How should test sample results be interpreted and categorized in real-time RT-PCR diagnostic assays? Expert Guide

Accurate interpretation of real-time RT-PCR results hinges on two factors: the Ct value and the shape of the amplification curve. Test samples are categorized into three primary groups: a positive result requires a Ct value below a validated threshold (such as Ct < 33) and a clear sigmoidal amplification curve; an inconclusive result occurs when a sample yields a high Ct but still displays a sigmoidal curve, demanding confirmatory re‑testing; and a negative result is characterized by either no detectable Ct or a high Ct with a flat or linear curve that reflects probe degradation or non‑specific background rather than genuine target amplification.

The core principle is that no single number can define a positive result—both the cycle threshold and the amplification plot morphology must be evaluated together. Inconclusive signals with high Ct values and genuine sigmoidal shape are not failures but prompts for re‑extraction and re‑testing to resolve the ambiguity, while flat late‑cycle traces should be dismissed as background.

The Two Pillars of Result Interpretation: Ct Value and Curve Morphology

A diagnostic decision cannot be reduced to a Ct number alone. Every real‑time PCR instrument visualizes the amplification in two complementary ways, and both must be examined.

The Meaning of the Ct Value

The threshold cycle (Ct) is the cycle number at which the fluorescence signal crosses a defined threshold, typically set in the exponential amplification phase. Lower Ct values (e.g., <30) indicate abundant starting template and a robust reaction. Higher Ct values (e.g., >33) correspond to low copy numbers, where stochastic effects and background noise become more significant. Because the exact Ct threshold that separates true positive from noise varies between assays, laboratories must establish their own validated cut‑off based on analytical sensitivity studies, standard‑curve linearity, and observed limit of detection.

The Diagnostic Power of the Amplification Curve Shape

The shape of the amplification plot reveals whether fluorescence increase is due to specific target amplification or an artifact. A true positive curve is sigmoidal: an initial flat baseline, a sharp exponential rise, and a plateau phase. A linear or slowly rising curve at high cycles is typical of probe degradation, non‑specific binding, or well‑to‑well optical fluctuations, not genuine target amplification. An objective interpretation protocol therefore mandates that a positive call requires a distinct sigmoidal shape; a high‑Ct sample that fails this shape check is never classified as positive.

Defining Your Assay’s Interpretation Algorithm

A standardized categorization scheme eliminates subjectivity and ensures that different operators—and different runs—reach the same conclusion.

Validated Ct Cut-offs

Many diagnostic protocols set a clear positive limit around Ct < 32–34, while supplementary references show that some assays use Ct < 30 as a “strong positive” and Ct 30–35 as “weak positive/inconclusive.” The primary guidance we follow here uses Ct < 33 as the positive threshold, based on a validated assay where this cut‑off balances sensitivity and specificity. These numbers are not arbitrary; they emerge from standard‑curve experiments in which a ten‑fold dilution series yields R² > 0.975, a slope between ‑3.0 and ‑3.9 (efficiency 80–110 %), and a correlation between Ct and copy number that justifies the chosen boundary.

Curve Assessment and Background Rejection

A positive call requires both a Ct below the cut‑off and a visually confirmed sigmoidal curve. Samples with Ct > 33 are evaluated by curve morphology:

• A sigmoidal curve at high Ct becomes inconclusive—true weak positivity cannot be excluded.
• A flat or linear trace with minimal fluorescence rise is considered negative or likely negative, often caused by probe degradation or non‑specific reagent interactions. In all cases, the batch is valid only if controls perform correctly: positive control yields a strong signal around Ct 20, no‑template control shows no Ct, and the passive reference dye (e.g., ROX) confirms normalization.

Managing Inconclusive and Challenging Signals

High‑Ct sigmoidal samples sit in a diagnostic grey zone. Mishandling them can lead to false‑positive or false‑negative reports.

The Inconclusive Zone

Inconclusive results are not “weak positives” to be reported directly; they are a request for more information. The underlying biology may reflect a very low viral load, sampling variability, or early‑stage infection, but it can also arise from trace contamination that nevertheless generates a sigmoidal curve. For this reason, inconclusive samples must be re‑tested starting from the primary specimen material (i.e., a new extraction), not simply re‑run from the same extract.

Re‑testing Strategy

The accepted workflow for inconclusive samples is:

1. Re‑extract nucleic acid from the original patient or sample matrix.
2. Run the purified material in duplicate or triplicate wells.
3. Interpret the outcome:
   • If both replicates give Ct values that closely agree and exhibit sigmoidal curves, the sample is considered positive.
   • If both are negative (no Ct), the sample is reported as negative.
   • If one is positive and one negative, the result remains inconclusive; additional replicates or an orthogonal method (e.g., viral isolation, sequencing) may be required. This strategy aligns with IVD industry recommendations that high‑Ct results must be confirmed through duplicate testing from fresh material to rule out random low‑level contamination or extraction inefficiency.

The Role of Controls in Validating Results

No sample can be interpreted in isolation. A run is only trustworthy when all controls meet pre‑established criteria.

• Positive Control (PC): A known template concentration should produce a Ct near 20, confirming that enzymes, primers, and probes are functional. The PC should fall within two standard deviations of historical mean Ct values.
• No‑Template Control (NTC): Must show no Ct and no significant baseline rise, guaranteeing that reagents and processing are contamination‑free.
• Passive Reference Dye Normalization: Dyes like ROX correct for optical artifacts, pipetting variation, and bubbles, ensuring that reporter fluorescence changes reflect true amplification.

A sample is positive only when a valid Ct is detected, the amplification curve is sigmoidal, and all controls pass. If the NTC shows a late linear rise or the PC shifts unexpectedly, the entire batch is invalid and must be repeated.

Understanding the Trade-offs

Every interpretation algorithm involves compromises between sensitivity, specificity, and operational practicality.

• False‑positive risk at high Ct: Raising the positive Ct cut‑off (e.g., using Ct 38) increases sensitivity but can classify non‑specific linear signals or low‑level contamination as positive. This can lead to unnecessary clinical actions and erode confidence in the assay.
• False‑negative risk with strict cut‑offs: A very low cut‑off (e.g., Ct 30) may miss genuine low‑copy infections, especially in surveillance settings where early detection matters.
• Subjective curve interpretation: Relying on visual inspection of sigmoidal shape requires trained operators. Automated algorithms can help, but malformed curves (e.g., slow initial rise with a late exponential phase) can trick both humans and software.
• Resource burden of re‑testing: Mandating duplicate re‑extraction for all inconclusive results increases hands‑on time and reagent costs. Laboratories must balance the risk of over‑calling noise against the operational cost of thorough confirmation.
• Assay‑specific thresholds: The exact Ct breakpoint (e.g., 33 vs. 32 vs. 35) is not universal. Adopting a published cut‑off without local validation can degrade performance if instruments, reagents, or sample types differ. The primary reference’s Ct 33 is a sensible starting point, but it must be verified through in‑house standard‑curve experiments.

Making the Right Choice for Your Diagnostic Goal

Your interpretation protocol should reflect the intended use of the assay and the consequences of each result category. Adapt the algorithm to your primary focus.

• If your primary focus is high sensitivity for screening: Use a Ct cut‑off in the 33–35 range, but enforce rigorous curve‑shape evaluation. Treat all high‑Ct sigmoidal samples as inconclusive and re‑test from primary material to avoid reporting false negatives from missed low‑level infections.
• If your primary focus is absolute specificity to prevent false positives: Set a stricter positive threshold (e.g., Ct 30–32) and classify all samples above this cut‑off as negative unless a perfect sigmoidal curve and duplicate re‑extraction confirm a weak positive. Regularly verify NTC cleanliness and reagent integrity to eliminate background signals.
• If your primary focus is operational efficiency and fast turnaround: Automate curve analysis with software that rejects non‑sigmoidal traces, and define a single‑replicate protocol for clear positives/negatives while reserving re‑testing only for the narrow inconclusive band (e.g., Ct 33–36 with sigmoidal shape). This minimizes hands‑on time without sacrificing diagnostic rigor.
• If your primary focus is compliance with IVD regulatory standards: Document the entire validation package—standard‑curve parameters (R², slope, efficiency), control acceptance criteria, and the statistical rationale for your Ct cut‑off. Ensure that re‑testing and confirmatory steps are described in the standard operating procedure, and use high‑purity raw materials and consistent control reagents to guarantee batch‑to‑batch stability.

Ultimately, the goal is not to follow a universal number but to build an interpretation framework that is transparent, validated for your specific assay, and flexible enough to handle the grey‑zone results that every real‑time PCR user will eventually encounter.

Summary Table:

Developing or optimizing your diagnostic assays? At CamelBio, we provide diagnostic manufacturers, laboratories, and research institutes with one-stop access to high-quality IVD raw materials, technical services, and expert consulting—covering every stage from concept to clinic. Enhance your RT-PCR assay accuracy and supply reliability by contacting our expert team today!